No connection

Search Results

BKD vs SUPN

BKD
Brookdale Senior Living Inc.
BEARISH
Price
$12.95
Market Cap
$3.08B
Sector
Healthcare
AI Confidence
85%
SUPN
Supernus Pharmaceuticals, Inc.
NEUTRAL
Price
$51.39
Market Cap
$2.96B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BKD
--
SUPN
--
Forward P/E
BKD
-23.33
SUPN
12.18
P/B Ratio
BKD
-462.5
SUPN
2.78
P/S Ratio
BKD
1.0
SUPN
4.12
EV/EBITDA
BKD
18.07
SUPN
60.62

Profitability

Gross Margin
BKD
27.57%
SUPN
89.63%
Operating Margin
BKD
2.36%
SUPN
-28.9%
Profit Margin
BKD
-9.95%
SUPN
-5.36%
ROE
BKD
-212.27%
SUPN
-3.68%
ROA
BKD
0.92%
SUPN
-2.09%

Growth

Revenue Growth
BKD
4.2%
SUPN
21.5%
Earnings Growth
BKD
--
SUPN
--

Financial Health

Debt/Equity
BKD
--
SUPN
0.04
Current Ratio
BKD
0.84
SUPN
1.91
Quick Ratio
BKD
0.5
SUPN
1.47

Dividends

Dividend Yield
BKD
--
SUPN
--
Payout Ratio
BKD
0.0%
SUPN
0.0%

AI Verdict

BKD BEARISH

The Advanced Deterministic Scorecard reveals a deeply concerning financial profile for Brookdale Senior Living (BKD), with a Piotroski F-Score of just 2/9 indicating severe weakness in fundamental health. Despite strong recent price performance (+163.2% over 1Y), the company is unprofitable (ROE: -212.27%, Profit Margin: -9.95%), carries significant liquidity risk (Current Ratio: 0.84), and has consistently missed earnings estimates—0 out of the last 4 quarters beaten, with an average surprise of -101.87%. Valuation metrics are distorted (Price/Book: -462.50, Forward P/E: -23.33) due to negative equity and earnings, while the lack of an Altman Z-Score suggests potential distress risk. Analysts rate it a 'strong_buy' but with only 4 analysts and no meaningful insider activity, the bullish sentiment lacks conviction.

Strengths
Revenue growth of 4.20% YoY shows modest top-line resilience in a challenging senior care environment
Gross margin of 27.57% indicates some operational efficiency at the core service level
Price/Sales ratio of 1.00 is reasonable relative to unprofitable peers in the healthcare sector
Risks
Piotroski F-Score of 2/9 signals extreme financial distress and poor earnings quality
Negative book value and ROE of -212.27% indicate eroding shareholder equity and likely balance sheet insolvency
Current Ratio of 0.84 and Quick Ratio of 0.50 reveal acute liquidity risk and inability to meet short-term obligations
SUPN NEUTRAL

SUPN presents a contradictory profile, characterized by a weak Piotroski F-Score of 2/9 and bearish insider sentiment (30/100). Despite these fundamental warnings, the company shows strong top-line growth (21.5% YoY) and maintains a very low debt-to-equity ratio of 0.04. Analysts remain highly optimistic with a 'Strong Buy' consensus and a target price of $63.17, suggesting a disconnect between current operational health and future growth expectations. The stock is currently a speculative play where strong revenue growth is fighting against deteriorating fundamental health metrics.

Strengths
Strong revenue growth of 21.50% YoY
Very low leverage with a Debt/Equity ratio of 0.04
High Gross Margin of 89.63%
Risks
Weak fundamental health indicated by a Piotroski F-Score of 2/9
Negative operating margins (-28.90%) indicating inefficiency
Heavy insider selling totaling $9.00M in the last 6 months

Compare Another Pair

BKD vs SUPN: Head-to-Head Comparison

This page compares Brookdale Senior Living Inc. (BKD) and Supernus Pharmaceuticals, Inc. (SUPN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile